← Markets

The Chemours Company

CC · NYSE

Market closed$17.52$0.190000 (+1.10%)After hours $17.87 · +2.00%

Key statistics

Previous close$17.33
Open$17.30
Day high$17.87
Day low$17.27
52-week high$28.67
52-week low$10.44
Market cap2.63B
Volume1.52M
Average volume2.76M
P/E ratio19.91
Forward P/E3.99
EPS0.88
Dividend yield+2.00%

Market context

Why it moved

Chemours (CC) edged higher, supported by fresh institutional investment disclosures showing multiple large funds initiating or expanding positions in the stock, which helped offset broader market weakness driven by AI sell-offs and rising oil prices amid escalating US-Iran tensions.

SjlMarketbeatPbsOsceolaclerkInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Chemours closed modestly higher, outperforming the broader materials sector (XLB), as Wall Street attention focuses on its compelling valuation case. BMO Capital reiterated a Buy with a $26 target while Mizuho kept an Outperform rating despite trimming its target to $25, still implying over 30% upside. The stock trades at just 0.5x P/S versus a ~1.1x industry average, and analysis published today notes it screens as undervalued across six valuation metrics despite a 51% year-to-date gain. Investors continue to weigh Chemours' exposure to AI-driven demand for technology materials against lingering legal and regulatory risks.

1.0964

July 17, 2026Chemours Company shares tumbled roughly 6.4% on above-average volume, giving back a portion of its impressive 51% year-to-date run even as analysts maintain a bullish outlook. BMO Capital holds a Buy rating with a $26 price target and Mizuho kept its Outperform rating (target cut to $25), both implying significant upside from current levels, with the stock still screening as undervalued across six valuation metrics — including a P/S of ~0.5x versus an industry average of ~1.1x. The broader Basic Materials sector (XLB) closed nearly flat, suggesting the selloff was company-specific rather than sector-driven, with investors potentially locking in gains ahead of Q2 earnings season amid a mixed macro backdrop dominated by tech weakness and ongoing Middle East geopolitical tensions.

-6.3749

July 16, 2026Chemours closed modestly lower as the specialty chemicals sector faced mixed sentiment, with the Materials ETF (XLB) also retreating during the session. Analyst attention remains supportive, however: BMO Capital reiterated a Buy with a $26 target and Mizuho kept its Outperform rating despite trimming its target to $25 — both well above current levels and implying meaningful upside. The stock trades roughly 11% below even the Street's lowest price target of $21, reinforcing the 'undervalued' thesis among bulls heading into Q2 earnings season.

-0.6441

July 15, 2026Chemours gained nearly 3% on above-average volume, outperforming the broader materials sector (XLB closed flat) as a cooler-than-expected June CPI report — headline inflation falling to 3.5% from 4.2% — lifted investor sentiment toward industrials and specialty chemicals. The softer inflation data eased concerns about further Fed rate hikes, providing a tailwind for input-cost-sensitive chemical producers. In after-hours trading, shares gave back a portion of those gains amid lingering uncertainty around Middle East tensions and rising crude oil prices.

2.8146

July 14, 2026Chemours rose nearly 2% Monday, outperforming the broader basic materials sector (XLB closed lower) even as equity markets sold off amid renewed U.S.-Iran tensions that sent oil prices surging. The specialty chemicals company benefited from positive media sentiment and analyst consensus pointing to a $24.10 price target — roughly 33% above current levels. Supportive sector dynamics, including Chinese supply restraint keeping fluorochemical and refrigerant gas prices elevated, are adding to the constructive backdrop as investors await Q2 earnings season.

1.7406

July 10, 2026Chemours gained over 2% during the session, outperforming the basic materials sector, even as a New York Attorney General lawsuit naming the company alongside 3M, DuPont, and Corteva over decades of PFAS 'forever chemicals' pollution weighed on peers. The litigation adds to an already complex regulatory picture — Chemours recently settled with the EPA and West Virginia for $112.5 million in penalties and mitigation projects — though analysts at Simply Wall St. see the settlement as clarifying long-term compliance obligations, with a fair value estimate of $26.33 implying meaningful upside.

2.4152

July 10, 2026Chemours shares fell sharply, pressured by a new lawsuit from New York Attorney General Letitia James targeting the company alongside 3M, DuPont, Corteva, and others over decades of alleged PFAS 'forever chemicals' pollution from consumer products. The legal action compounds existing PFAS overhang — just days after Chemours agreed to a separate $112.5 million EPA/West Virginia settlement — and rekindled investor concerns about open-ended environmental liabilities, even as BMO Capital maintained a Buy rating with a $26 target and some analysts view the stock as meaningfully undervalued.

-5.3863

July 9, 2026Chemours fell during the regular session amid a broad market risk-off selloff triggered by President Trump declaring the U.S.-Iran peace framework 'over,' sending oil prices surging over 5% and stoking inflation fears. Company-specific headwinds compounded the pressure, as investors continued to reassess Chemours' $450 million PFAS settlement following political backlash from affected communities in North Carolina, reigniting concerns about long-term environmental liabilities and balance sheet strain from its high leverage. Despite the session decline, shares rebounded in after-hours trading, and BMO Capital reiterated its Buy rating with a $26 price target — implying roughly 40% upside — pointing to the company's high-margin Thermal & Specialized Solutions unit as a key earnings anchor.

-2.4934

Simply Wall Street · July 16, 2026Chemours (CC) Stock Looks Below Fair Value Even After A 51% RunNorth Carolina Health News · June 25, 2026Chemours looks to settle federal PFAS case for $450 million. NC wasn’t at the table.
Mt Newswire · July 9, 20263M, DuPont, Corteva, Chemours Sued by New York AG Over Toxic Pollution From Consumer Products
Mt Newswire · July 9, 2026Street Color: 3M, Chemours Among Firms Sued by New York Attorney General Over Alleged PFAS Pollution
Benzinga · July 9, 2026New York Attorney General's Suit Names 3M, Chemours, Corteva, DuPont De Nemours; New York Attorney General Sues Chemical Companies Over Alleged Toxic Pollution from Consumer Products
Benzinga · July 1, 2026Mizuho Maintains Outperform on Chemours, Lowers Price Target to $25
Mt Newswire · June 24, 2026Chemours to Pay $22.5 Million Penalty, Implement Relief Programs to Resolve 'Forever Chemicals' Environmental Claims
Benzinga · June 24, 2026U.S. Department Of Justice Announces Chemours Agrees To Pay $450M Settlement Charges Over Alleged Release Of Per- And Polyfluoroalkyl Substances In Three States
Benzinga · May 21, 2026JP Morgan Maintains Neutral on Chemours, Raises Price Target to $22
Mt Newswire · May 11, 2026Chemours Reiterated 2026 Guidance but Investors Wanted Stronger Signal, RBC Says

Peers

S&P 500SPX · $7,457.69-1.01%AdvanSix Inc.ASIX · $20.79+0.14%Dow Inc.DJI · $29.92+2.12%Eastman Chemical CompanyEMN · $68.60-0.81%Huntsman CorporationHUN · $11.79-0.59%Kronos Worldwide, Inc.KRO · $6.58-1.50%Tronox Holdings plcTROX · $5.84+1.21%Venator Materials PLCVNTRF · $28.000.00%Celanese CorporationCE · $45.70-0.17%Albemarle CorporationALB · $120.78+1.10%Olin CorporationOLN · $21.99+0.05%Arkema S.A.AKE.PA · €55.75-1.50%